Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The study reveals a potential link between concussions and the activation of dormant viruses, which may lead to ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Imagine a world where the mind remains sharp, even as the years pass by. Scientists are on the brink of a breakthrough that ...

Roche Holding, Novartis, and Eli Lilly & Company Dominate the Competitive Landscape Global Central Nervous System ...

The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...

Studies have long warned that blows to the head may raise the risk of neurodegenerative conditions. Now, scientists believe ...

POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...

Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow ...

New research suggests that concussions and repetitive head trauma may reactivate dormant viruses like HSV-1 in the brain, potentially triggering neurodegenerative diseases such as Alzheimer’s.

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...